Biotechnology

Oncolytics Biotech

Oncolytics Biotech released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0823 (forecast USD -0.048)

Oncolytics Biotech released FY2025 Annual Earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3 (forecast USD -0.2634)

Oncolytics Biotech released FY2025 Q4 earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0835 (forecast USD -0.0627)

Oncolytics Biotech Announces Precision Oncology Market Growth Forecast

Oncolytics Biotech Reports Positive Results for Pelareorep and Atezolizumab Combination in Anal Cancer Study

Oncolytics Biotech released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -0.2067

Oncolytics Biotech released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.102 (forecast USD -0.0616)

Oncolytics Biotech Reports 30% Response Rate for Anal Cancer Combination Therapy

Oncolytics Biotech released FY2025 Q2 earnings on August 8 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0494 (forecast USD -0.0737)

Oncolytics Biotech released FY2025 Semi-Annual Earnings on August 8 Pre-Market EST, with actual revenue of USD 0 and EPS of USD -0.1045

Oncolytics Biotech to Release FY2025 Q2 Earnings on August 8 Pre-Market EST, Forecast Revenue USD 0, EPS USD -0.0729

Oncolytics plans to start pancreatic cancer immunotherapy trials by the end of 2025

Oncolytics Biotech Senior Official Buys Stocks

Oncolytics Biotech Exec Buys Shares

Oncolytics Showcases Pelareorep's Efficacy Data for Cancer Treatment

Oncolytics to Hold pelareorep Webinar

Jones Trading Downgrades Oncolytics Biotech Stock Rating

Oncolytics Biotech stock rises, Jones Trading downgrades rating

Global oncology market rapidly expanding

Oncolytics Biotech Receives Analyst Ratings and Target Prices

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ONCY

Oncolytics reported a 19.5-month median duration of response in second-line KRAS-mutant MSS metastatic colorectal cancer (mCRC) with its REO 022: pelareorep combination therapy, significantly exceeding the historical benchmark of 4-6 months. The objective response rate was 33%, three times higher than standard care rates. The company is enrolling for a randomized Phase 2 trial and is in discussions with the FDA for potential accelerated approval. Pelareorep has Fast Track designation for colorectal and pancreatic cancer, and Oncolytics is seeking strategic partnerships for further development.

TradingView

Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC

Oncolytics Biotech rose 9.95% in after-hours trading; Compass Therapeutics had a trading volume of USD 118,000; Intellia Therapeutics rose 1.44% in after-hours trading, with a trading volume of USD 85,300; Absci fell 1.23% in after-hours trading, with a trading volume of USD 50,500

Price Alert

Compass Therapeutics

Intellia Therap

Absci

U.S. stock night trading volatility: Oncolytics Biotech rose nearly 10% in after-hours trading, boosted by FDA key study protocol enhancing market confidence

Oncolytics Biotech Inc announced a successful Type C meeting with the U.S. FDA regarding the pivotal clinical study design for pelareorep, aimed at treating unresectable metastatic squamous cell carcinoma of the anal canal. CEO Jared Kelly expressed gratitude for the FDA's guidance in establishing an efficient approval pathway. The company's shares are currently trading up $0.02 at $1.05.

Baystreet

Stocks in Play: Oncolytics Biotech Inc

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study | ONCY Stock News

StockTitan

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study | ONCY Stock News

Oncolytics Biotech(ONCY.US)

Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC

U.S. stock night trading volatility: Oncolytics Biotech rose nearly 10% in after-hours trading, boosted by FDA key study protocol enhancing market confidence

Stocks in Play: Oncolytics Biotech Inc

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study | ONCY Stock News